FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206041748> ?p ?o ?g. }

• W3206041748 endingPage "31.e9" @default.
• W3206041748 startingPage "31.e1" @default.
• W3206041748 abstract "Hematopoietic stem cell transplantation (HSCT) may be used to consolidate chimeric antigen receptor (CAR) T cell therapy-induced remissions for patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL), but little is known about the factors impacting overall survival (OS) and event-free survival (EFS) for post-CAR hematopoietic stem cell transplantation (HSCT). The present study's primary objective was to identify factors associated with OS and EFS for consolidative HSCT following CAR-induced complete remission (CR) in transplantation-naïve patients. Secondary objectives included evaluation of OS/EFS, relapse-free survival and cumulative incidence of relapse for all patients who proceeded to HSCT, stratified by first and second HSCT, as well as the tolerability of HSCT following CAR-induced remission. This was a retrospective review of children and young adults enrolled on 1 of 3 CAR T cell trials at the National Cancer Institute targeting CD19, CD22, and CD19/22 (ClinicalTrials.gov identifiers NCT01593696, NCT02315612, and NCT03448393) who proceeded directly to HSCT following CAR T cell therapy. Between July 2012 and February 2021, 46 children and young adults with pre-B ALL went directly to HSCT following CAR therapy. Of these patients, 34 (74%) proceeded to a first HSCT, with a median follow-up of 50.8 months. Transplantation-naïve patients were heavily pretreated prior to CAR T cell therapy (median, 3.5 lines of therapy; range, 1 to 12) with significant prior immunotherapy exposure (blinatumomab, inotuzumab, and/or CAR T cell therapy in patients receiving CD22 or CD19/22 constructs (88%; 15 of /17)). Twelve patients (35%) had primary refractory disease, and the median time from CAR T cell infusion to HSCT Day 0 was 54.5 days (range, 42 to 127 days). The median OS following first HSCT was 72.2 months (95% confidence interval [CI], 16.9 months to not estimable [NE]), with a median EFS of 36.9 months (95% CI, 5.2 months to NE). At 12 and 24 months, the OS was 76.0% (95% CI, 57.6% to 87.2%) and 60.7% (95% CI, 40.8% to 75.8%), respectively, and EFS was 64.6% (95% CI, 46.1% to 78.1%) and 50.9% (95% CI, 32.6% to 66.6%), respectively. The individual factors associated with both decreased OS and EFS in univariate analyses for post-CAR consolidative HSCT in transplantation-naïve patients included ≥5 prior lines of therapy (not reached [NR] versus 12.4 months, P = .014; NR versus 4.8 months, P = .063), prior blinatumomab therapy (NR versus 16.9 months, P = .0038; NR versus 4.4 months, P = .0025), prior inotuzumab therapy (NR versus 11.5 months, P = .044; 36.9 months versus 2.7 months, P = .0054) and ≥5% blasts (M2/M3 marrow) pre-CAR T cell therapy (NR versus 17 months, P = .019; NR versus 12.2 months, P = .035). Primary refractory disease was associated with improved OS/EFS post-HSCT (NR versus 21.9 months, P = .075; NR versus 12.2 months, P = .024). Extensive prior therapy, particularly immunotherapy, and high disease burden each individually adversely impacted OS/EFS following post-CAR T cell consolidative HSCT in transplantation-naïve patients, owing primarily to relapse. Despite this, HSCT remains an important treatment modality in long-term cure. Earlier implementation of HSCT before multiply relapsed disease and incorporation of post-HSCT risk mitigation strategies in patients identified to be at high-risk of post-HSCT relapse may improve outcomes." @default.
• W3206041748 created "2021-10-25" @default.
• W3206041748 creator A5007115015 @default.
• W3206041748 creator A5030044268 @default.
• W3206041748 creator A5035242151 @default.
• W3206041748 creator A5044239219 @default.
• W3206041748 creator A5071031431 @default.
• W3206041748 creator A5076065961 @default.
• W3206041748 creator A5084974669 @default.
• W3206041748 creator A5087779758 @default.
• W3206041748 date "2022-01-01" @default.
• W3206041748 modified "2023-10-07" @default.
• W3206041748 title "Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation" @default.
• W3206041748 cites W1491993932 @default.
• W3206041748 cites W2015018636 @default.
• W3206041748 cites W2023956264 @default.
• W3206041748 cites W2037522752 @default.
• W3206041748 cites W2091001903 @default.
• W3206041748 cites W2113030986 @default.
• W3206041748 cites W2132827894 @default.
• W3206041748 cites W2148428061 @default.
• W3206041748 cites W2157460080 @default.
• W3206041748 cites W2334112953 @default.
• W3206041748 cites W2379365975 @default.
• W3206041748 cites W2519921873 @default.
• W3206041748 cites W2606654718 @default.
• W3206041748 cites W2757776684 @default.
• W3206041748 cites W2787301955 @default.
• W3206041748 cites W2787621143 @default.
• W3206041748 cites W2790108618 @default.
• W3206041748 cites W2891679914 @default.
• W3206041748 cites W2905654445 @default.
• W3206041748 cites W2915597716 @default.
• W3206041748 cites W2919051790 @default.
• W3206041748 cites W2935806086 @default.
• W3206041748 cites W2939818551 @default.
• W3206041748 cites W2944689312 @default.
• W3206041748 cites W2944872008 @default.
• W3206041748 cites W2969718077 @default.
• W3206041748 cites W2981626013 @default.
• W3206041748 cites W2987469470 @default.
• W3206041748 cites W2999407263 @default.
• W3206041748 cites W3000703533 @default.
• W3206041748 cites W3008757142 @default.
• W3206041748 cites W3016233874 @default.
• W3206041748 cites W3021616332 @default.
• W3206041748 cites W3091258055 @default.
• W3206041748 cites W3095459105 @default.
• W3206041748 cites W3096139078 @default.
• W3206041748 cites W3097334460 @default.
• W3206041748 cites W3101364852 @default.
• W3206041748 cites W3112175219 @default.
• W3206041748 cites W3119718700 @default.
• W3206041748 cites W3128100928 @default.
• W3206041748 cites W3131243133 @default.
• W3206041748 cites W3134763925 @default.
• W3206041748 cites W3135688349 @default.
• W3206041748 cites W3138004978 @default.
• W3206041748 cites W3146530070 @default.
• W3206041748 cites W3154217117 @default.
• W3206041748 cites W3160154881 @default.
• W3206041748 cites W3178325975 @default.
• W3206041748 cites W4226180206 @default.
• W3206041748 doi "https://doi.org/10.1016/j.jtct.2021.10.011" @default.
• W3206041748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34687939" @default.
• W3206041748 hasPublicationYear "2022" @default.
• W3206041748 type Work @default.
• W3206041748 sameAs 3206041748 @default.
• W3206041748 citedByCount "8" @default.
• W3206041748 countsByYear W32060417482022 @default.
• W3206041748 countsByYear W32060417482023 @default.
• W3206041748 crossrefType "journal-article" @default.
• W3206041748 hasAuthorship W3206041748A5007115015 @default.
• W3206041748 hasAuthorship W3206041748A5030044268 @default.
• W3206041748 hasAuthorship W3206041748A5035242151 @default.
• W3206041748 hasAuthorship W3206041748A5044239219 @default.
• W3206041748 hasAuthorship W3206041748A5071031431 @default.
• W3206041748 hasAuthorship W3206041748A5076065961 @default.
• W3206041748 hasAuthorship W3206041748A5084974669 @default.
• W3206041748 hasAuthorship W3206041748A5087779758 @default.
• W3206041748 hasBestOaLocation W32060417481 @default.
• W3206041748 hasConcept C10882517 @default.
• W3206041748 hasConcept C121608353 @default.
• W3206041748 hasConcept C126322002 @default.
• W3206041748 hasConcept C143998085 @default.
• W3206041748 hasConcept C147483822 @default.
• W3206041748 hasConcept C197934379 @default.
• W3206041748 hasConcept C203014093 @default.
• W3206041748 hasConcept C2777408962 @default.
• W3206041748 hasConcept C2777701055 @default.
• W3206041748 hasConcept C2778020697 @default.
• W3206041748 hasConcept C2778375690 @default.
• W3206041748 hasConcept C2778957590 @default.
• W3206041748 hasConcept C28328180 @default.
• W3206041748 hasConcept C2911091166 @default.
• W3206041748 hasConcept C3875195 @default.
• W3206041748 hasConcept C54355233 @default.
• W3206041748 hasConcept C71924100 @default.

• next